Welcome to our dedicated page for Ironwood Pharmaceuticals - news (Ticker: $IRWD), a resource for investors and traders seeking the latest updates and insights on Ironwood Pharmaceuticals - stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ironwood Pharmaceuticals -'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ironwood Pharmaceuticals -'s position in the market.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in The Citizens JMP Life Sciences Conference on May 13, 2024. The management will engage in a fireside chat at 10:00 a.m. ET at the New York Hilton Midtown. The event will be live streamed on the company's website. A replay will be available for 1 year.
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will present new data on once-weekly apraglutide in short bowel syndrome with intestinal failure (SBS-IF) at the 2024 Digestive Disease Week®. The pivotal Phase III STARS study's findings and the STARS Nutrition Study will be highlighted, alongside additional posters focusing on linaclotide, irritable bowel syndrome, and functional constipation. Apraglutide data from the STARS trial aims to reduce parenteral support (PS) dependency in adult SBS-IF patients, with plans for a new drug application submission to the FDA.
